- Investing.com
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Financial Resilience | Outset Medical's Q3 2024 earnings surpassed expectations, leading to raised revenue guidance and improved financial stability through strategic financing |
Transformative Tactics | Delve into Outset Medical's commercial restructuring efforts, including new sales teams and enhanced processes, poised to drive growth in 2025 and beyond |
Product Innovation | Explore the impact of the newly approved Tablo Cart, expected to revitalize sales and potentially capture a larger market share in the dialysis equipment secto |
Market Dynamics | Analysts project high-teens growth rates from 2025 to 2027, with an average price target of $4, reflecting cautious optimism amid market volatility |
Metrics to compare | OM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.7x | −3.9x | −0.5x | |
PEG Ratio | −0.06 | −0.25 | 0.00 | |
Price/Book | 1.9x | 2.9x | 2.6x | |
Price / LTM Sales | 2.7x | 3.3x | 3.2x | |
Upside (Analyst Target) | 30.5% | 38.8% | 42.0% | |
Fair Value Upside | Unlock | 8.1% | 6.6% | Unlock |